RESUMO
BACKGROUND: In newborns with hemolysis, the direct antiglobulin test (DAT) and indirect antiglobulin test (IAT) play a key role in demonstrating the presence of an immune cause. We aimed to emphasize the importance of IAT in mothers of DAT-positive babies. METHODS: DAT was performed with forward blood grouping on cord blood in term babies who were born between September 2020 and September 2022. IAT was performed in the mothers of the babies who were found to have a positive DAT and antibody identification was performed in the mothers who were found to have a positive IAT. Specific antibodies detected and identified were associated with the clinical course. RESULTS: The study included 2769 babies and their mothers. The prevalence of DAT positivity was found to be 3.3% (87 of 2661). In DAT-positive babies, the rate of ABO incompatibility was 45.9%, the rate of RhD incompatibility was 5.7% and the rate of RhD and ABO incompatibility in association was 10.3%. The rate of subgroup incompatibility and other red blood cell antibodies was 18.3%. Phototherapy was applied because of indirect hyperbilirubinemia in 16.6% of the DAT-negative babies and in 51.5% of the DAT-positive babies. The need for phototherapy was significantly higher in DAT-positive infants (p < 0.01). Severe hemolytic disease of the newborn, bilirubin level, duration of phototherapy and use of intravenous immunoglobulin were found to be significantly higher in the babies whose mothers were IAT positive compared with the babies whose mothers were IAT negative (p < 0.01). CONCLUSIONS: IAT should be performed on all pregnant women. When screening with IAT is not performed during pregnancy, performing DAT in the baby plays a key role. We showed that the clinical course was more severe when mothers of DAT-positive babies were IAT positive.
Assuntos
Eritroblastose Fetal , Lactente , Recém-Nascido , Humanos , Feminino , Gravidez , Teste de Coombs , Estudos Retrospectivos , Eritroblastose Fetal/diagnóstico , Eritroblastose Fetal/epidemiologia , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Anticorpos , Progressão da Doença , Sistema ABO de Grupos SanguíneosRESUMO
The diagnosis of ABO hemolytic disease of the newborn (ABO HDN) has been the subject of considerable debate and clinical confusion. Its use as an overarching default diagnosis for hyperbilirubinemia in all ABO incompatible neonates regardless of serological findings is problematic and lacks diagnostic precision. Data on hemolysis indexed by carbon monoxide (CO) levels in expired air (ETCOc) and blood (COHbc) support an essential role for a positive direct antiglobulin test (DAT) in making a more precise diagnosis of ABO HDN. A working definition that includes ABO incompatibility, significant neonatal hyperbilirubinemia, and a positive DAT is needed to gain clarity and consistency in the diagnosis of ABO HDN. Absent a positive DAT, the diagnosis of ABO HDN is suspect. Instead, a negative DAT in a severely hyperbilirubinemic ABO incompatible neonate should trigger an exhaustive search for an alternative cause, a search that may require the use of targeted gene panels.
Assuntos
Eritroblastose Fetal , Hiperbilirrubinemia Neonatal , Recém-Nascido , Feminino , Humanos , Sistema ABO de Grupos Sanguíneos , Eritroblastose Fetal/diagnóstico , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Hiperbilirrubinemia Neonatal/diagnóstico , Hemólise , Teste de Coombs/métodosRESUMO
BACKGROUND: Daratumumab, a human anti-CD38 monoclonal antibody used to treat multiple myeloma, interferes with pretransfusion testing and can mask alloantibodies. Incidence of alloimmunization in patients on daratumumab has not been well characterized, and optimal transfusion guidelines regarding prophylactic antigen matching, accounting for both patient safety and efficiency, have not been well established for these patients. METHODS: Records of patients who received daratumumab between January 1, 2014 and July 2, 2019 were reviewed. Daratumumab interference with pretransfusion testing was managed by testing with reagent red blood cells (RBCs) treated with 0.2 M dithiothreitol. When daratumumab was present during antibody testing, patients were transfused with RBC units prophylactically matched for D, C, c, E, e, and K antigens per hospital policy. RESULTS: Out of 90 patients identified, 52 received a total of 638 RBC transfusions (average of 12.3 units per patient, SD 17.2, range 1-105, median 5 among those transfused). Alloantibodies existing before daratumumab initiation were identified in seven patients. No new alloantibodies were detected in any patients after starting daratumumab treatment. CONCLUSIONS: The incidence of alloimmunization in patients receiving daratumumab is low. Whether this is due to the effect of daratumumab, underlying pathophysiology, or other factors, is unknown. Because these patients require a large number of RBC transfusions overall and have little observed alloimmunization, phenotype matching (beyond RhD) may be unnecessary. Since the use of dithiothreitol cannot rule out the presence of anti-K, we recommend transfusion of ABO-compatible units, prophylactically matched for the D and K antigens only.
Assuntos
Anticorpos Monoclonais/imunologia , Antineoplásicos Imunológicos/imunologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Artefatos , Incompatibilidade de Grupos Sanguíneos/sangue , Tipagem e Reações Cruzadas Sanguíneas , Transfusão de Sangue , Eritrócitos/imunologia , Isoanticorpos/sangue , Mieloma Múltiplo/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Aloenxertos , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/uso terapêutico , Antineoplásicos Imunológicos/administração & dosagem , Antineoplásicos Imunológicos/uso terapêutico , Antígenos de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Incompatibilidade de Grupos Sanguíneos/epidemiologia , Tipagem e Reações Cruzadas Sanguíneas/métodos , Terapia Combinada , Ditiotreitol/farmacologia , Eritrócitos/efeitos dos fármacos , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Incidência , Isoanticorpos/biossíntese , Isoanticorpos/imunologia , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/tratamento farmacológico , Transplante AutólogoRESUMO
Fatal ABO-incompatible (ABOi) transfusion is one of the most common causes of transfusion-related death, but its reporting has been limited in Korea. We comprehensively reviewed ABOi transfusion events in Korea by analyzing cases reported in literature, Korean hemovigilance system (KOHEVIS) annual reports, and written judgments. Written judgments were assessed using a written judgment management system or a comprehensive legal information system. We found nine cases of ABOi transfusion events in written judgments (from 1953 to 2019), 16 in the KOHEVIS (from 2008 to 2018), and nine in published reports (from 1978 to 2019). One case was found in all three sources. Overall, we found 32 cases of ABOi transfusion events. Four cases died and 23 survived, while the outcomes for five were unavailable. ABOi transfusion errors occurred at the administration (50%, 16/32), sample (13%, 4/32), and testing (9%, 3/32) stages. The causes of errors were unavailable for nine cases (28%, 9/32). We report the status of ABOi transfusions in Korea and expect our results to contribute to the prevention of adverse reactions due to ABOi transfusion.
Assuntos
Sistema ABO de Grupos Sanguíneos , Incompatibilidade de Grupos Sanguíneos , Transfusão de Sangue , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Segurança do Sangue , Feminino , Rejeição de Enxerto , Humanos , Julgamento , Doadores Vivos , Masculino , República da CoreiaRESUMO
BACKGROUND: Most transplantation centers recognize a small patient population that unsuccessfully participates in all available, both living and deceased donor, transplantation programs for many years: the difficult-to-match patients. This population consists of highly immunized and/or ABO blood group O or B patients. METHODS: To improve their chances, Computerized Integration of Alternative Transplantation programs (CIAT) were developed to integrate kidney paired donation, altruistic/unspecified donation, and ABO and HLA desensitization. To compare CIAT with reality, a simulation was performed, including all patients, donors, and pairs who participated in our programs in 2015-2016. Criteria for inclusion as difficult-to-match, selected-highly immunized (sHI) patient were as follows: virtual panel reactive antibody >85% and participating for 2 years in Eurotransplant Acceptable Mismatch program. sHI patients were given priority, and ABO blood group incompatible (ABOi) and/or HLA incompatible (HLAi) matching with donor-specific antigen-mean fluorescence intensity (MFI) <8000 were allowed. For long-waiting blood group O or B patients, ABOi matches were allowed. RESULTS: In reality, 90 alternative program transplantations were carried out: 73 compatible, 16 ABOi, and 1 both ABOi and HLAi combination. Simulation with CIAT resulted in 95 hypothetical transplantations: 83 compatible (including 1 sHI) and 5 ABOi combinations. Eight sHI patients were matched: 1 compatible, 6 HLAi with donor-specific antigen-MFI <8000 (1 also ABOi), and 1 ABOi match. Six/eight combinations for sHI patients were complement-dependent cytotoxicity cross-match negative. CONCLUSIONS: CIAT led to 8 times more matches for difficult-to-match sHI patients. This offers them better chances because of a more favorable MFI profile against the new donor. Besides, more ABO compatible matches were found for ABOi couples, while total number of transplantations was not hampered. Prioritizing difficult-to-match patients improves their chances without affecting the chances of regular patients.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/imunologia , Técnicas de Apoio para a Decisão , Seleção do Doador , Antígenos HLA/imunologia , Histocompatibilidade , Transplante de Rim , Obtenção de Tecidos e Órgãos , Adulto , Incompatibilidade de Grupos Sanguíneos/complicações , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Tipagem e Reações Cruzadas Sanguíneas , Tomada de Decisão Clínica , Feminino , Humanos , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Resultado do TratamentoRESUMO
BACKGROUND: ABO subgroups or weaker variants of A or B are group A or B subjects whose erythrocytes give a weak or negative reaction serologically with anti-A or Anti - B antisera respectively. Occurrence of these subgroups may lead to an ABO discrepancy which often puts transfusion services in a quandary. ABO subgroups which present as ABO discrepancies can be missed if reverse grouping is not performed. AIM: This study was planned to estimate the prevalence of different subgroups which can present as an ABO discrepancy in Indian population, and provide an insight to transfusion services for identification of subgroups serologically. MATERIALS AND METHODS: A cross-sectional, analytical study was performed at a tertiary healthcare based blood bank on whole blood donors and patients from January 2017 to July 2018. All suspected type II and Type IV (with Anti-A1) ABO discrepant samples were projected to an algorithmic testing process, to confirm discrepancy and then narrow down to the probable subgroup. RESULTS: A total of 33 subgroup discrepancies; 26 of A group and 7 of B group were identified out of 73,380 patient and 35,279 donor samples tested for blood grouping. Following the algorithm, the overall prevalence of weak subgroups which can present as an ABO discrepancy was found to be 1 in 3293 or 0.03% in our population by serological testing. Out of the discrepancies caused by subgroups, the prevalence of subgroups of A were 0.0101%, 0.0018%, 0.0009%, 0.0027%, 0.0027% and 0.0018% for A2 with anti-A1, A3, Aend, Ax, Am and Ael respectively while those of B were 0.009%, 0.0009%, 0.0009% and 0.009% for B3, Bx, Bm and Bel respectively. CONCLUSION: Algorithmic approach for resolution of ABO discrepancies caused by subgroups helps in identifying the subgroup which is important because these individuals may be mistyped as group O individuals.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Algoritmos , Anticorpos/sangue , Doadores de Sangue , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Tipagem e Reações Cruzadas Sanguíneas , Transfusão de Sangue , Testes Sorológicos , Incompatibilidade de Grupos Sanguíneos/sangue , Incompatibilidade de Grupos Sanguíneos/imunologia , Estudos Transversais , Humanos , Índia , Valor Preditivo dos TestesRESUMO
INTRODUCTION: The alloimmunization of the ABO blood group system is involved in neonatal jaundice with a considerable overall prevalence. The role of ABO incompatibility is relatively little known. The purpose of this study was to investigate neonatal jaundice due to feto-maternal ABO incompatibilities and to determine the link between the hemolysins value in the mother and the degree of jaundice observed in the infant. METHODS: We conducted a cross-sectional study from June to November 2015. The study population was exclusively composed of moms who were blood type O with children who were a different blood type hospitalized in the Department of Neonatology at the Reference Hospital in the city of Yaoundé. Statistical analyses were performed using the GraphPadPrism 6 software with a confidence interval of 95%. RESULTS: Hemolysins frequency was of 20.58% (7/34) and anti-A hemolysin was the most common type (85.7%; 6/7). The new-born who had blood type B had a greater concentration of bilirubin levels compared to those of the AB group (p = 0.01). Multiparity was not associated with the presence of hemolysin (p = 0.8) as well as blood type of the infant was not associated with the occurrence of the hemolysins in the mother (p = 0.5). CONCLUSION: Early neonatal jaundice or protracted neonatal jaundice are also caused by hemolysins anti-A and anti-B derived from the allo-ABO immunization. A study on a larger sample is recommended for better assessment.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Autoanticorpos/análise , Ensaio de Atividade Hemolítica de Complemento/estatística & dados numéricos , Icterícia Neonatal , Mães , Adolescente , Adulto , Autoanticorpos/sangue , Incompatibilidade de Grupos Sanguíneos/sangue , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Incompatibilidade de Grupos Sanguíneos/epidemiologia , Camarões/epidemiologia , Estudos Transversais , Feminino , Hemólise , Humanos , Recém-Nascido , Icterícia Neonatal/sangue , Icterícia Neonatal/diagnóstico , Icterícia Neonatal/epidemiologia , Masculino , Mães/estatística & dados numéricos , Prevalência , Adulto JovemRESUMO
BACKGROUND: Liver transplantation usually requires blood transfusion, and a red blood cell (RBC) antibody screen is essential for the prevention of a hemolytic reaction. Since proper ABO-compatible grafts are lacking, ABO-incompatible living donor liver transplantation (ABO-i LDLT) with desensitization is a feasible therapy. Desensitization includes intravenous rituximab injection and plasmapheresis before surgery. CASE: A 60-year-old female was diagnosed with hepatitis B virus-related hepatocellular carcinoma and planned for ABO-i LDLT. She tested positive in a RBC antibody screen over two years; however, she tested negative for the test after desensitization. Clinicians noted the seroconversion during induction, and thus, a delay in the preparation of adequate packed RBC was unavoidable. CONCLUSIONS: Even when the latest RBC antibody screen is negative after immunosuppression, clinicians should consider the possibility of a prior positive result to promote safer medical treatment and management.
Assuntos
Sistema ABO de Grupos Sanguíneos/sangue , Incompatibilidade de Grupos Sanguíneos/sangue , Transplante de Fígado/efeitos adversos , Doadores Vivos , Soroconversão/fisiologia , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Evolução Fatal , Feminino , Humanos , Pessoa de Meia-IdadeAssuntos
Anemia/terapia , Incompatibilidade de Grupos Sanguíneos/urina , Transfusão de Eritrócitos/efeitos adversos , Reação Transfusional/urina , Dor Abdominal/etiologia , Adulto , Anemia/diagnóstico , Incompatibilidade de Grupos Sanguíneos/complicações , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Bradicardia/etiologia , Serviço Hospitalar de Emergência , Fadiga/etiologia , Feminino , Hidratação , Cefaleia/etiologia , Humanos , Hipertensão/etiologia , Ferro/uso terapêutico , Náusea/etiologia , Readmissão do Paciente , Reação Transfusional/complicações , Reação Transfusional/diagnóstico , Reação Transfusional/terapia , Vitamina B 12/uso terapêutico , Deficiência de Vitamina B 12/diagnóstico , Deficiência de Vitamina B 12/terapia , Complexo Vitamínico B/uso terapêuticoAssuntos
Reação Transfusional , Incompatibilidade de Grupos Sanguíneos/complicações , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Incompatibilidade de Grupos Sanguíneos/imunologia , Diagnóstico Diferencial , Hemólise , História do Século XVII , História do Século XX , Humanos , Reação Transfusional/diagnóstico , Reação Transfusional/história , Reação Transfusional/fisiopatologia , Reação Transfusional/terapiaAssuntos
Anemia/diagnóstico , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Doenças do Recém-Nascido/diagnóstico , Complicações na Gravidez/sangue , Sistema do Grupo Sanguíneo Rh-Hr/imunologia , Autoanticorpos/sangue , Feminino , Humanos , Recém-Nascido , Masculino , Gravidez , Índice de Gravidade de DoençaRESUMO
Sickle cell disease (SCD) is the most common monogenic disorder in sub-Saharan Africa (SSA). Blood transfusion to increase the oxygen carrying capacity of blood is vital in the management of many patients with SCD. However, red blood cell (RBC) alloimmunization is a major challenge to transfusions in these patients. Commonly in SSA, pretransfusion tests only involve ABO D grouping and compatibility without RBC antibody testing. Data on the frequency of RBC alloimmunization in patients with SCD in SSA are limited. We performed a systematic review and meta-analysis on available data on alloimmunization in transfused patients with SCD to determine the published prevalence of RBC alloimmunization in SCD patients in SSA. Six databases were systematically searched to identify relevant studies, without year or language restrictions. In all, 249 articles were identified and 15 met our selection criteria. The overall proportion of alloimmunization was 7.4 (95% confidence interval: 5.1-10.0) per 100 transfused patients. Antibodies against E, D, C, and K antigens accounted for almost half of antibody specificities, and antibodies to low- and high-frequency antigens were also common and represented almost 30% (20% to low-frequency antigens and 9% to high-frequency antigens) of specificities. Heterogeneity between studies was moderate, and meta-analysis found region of Africa as the major contributor to the heterogeneity. We also observed inconsistencies across studies in reporting of factors that may influence alloimmunization. This review provides an overview of the extent of the alloimmunization problem in SSA and provides a baseline against which to compare the effect of any interventions to reduce the alloimmunization risk.
Assuntos
Anemia Falciforme/terapia , Incompatibilidade de Grupos Sanguíneos/epidemiologia , Transfusão de Eritrócitos/efeitos adversos , Eritrócitos/imunologia , Reação Transfusional/epidemiologia , África Subsaariana , Anemia Falciforme/imunologia , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Incompatibilidade de Grupos Sanguíneos/imunologia , Humanos , Prevalência , Análise de Regressão , Reação Transfusional/diagnóstico , Reação Transfusional/imunologiaRESUMO
The severity of the hemolytic disease of the fetus and newborn (HDFN) due to Jra mismatch ranges from no symptoms to severe anemia that requires intrauterine and exchange transfusions. We encountered a newborn, born to a healthy mother having anti-Jra at 38â¯weeks of pregnancy, who had moderate anemia, a positive direct antiglobulin test (DAT) result, no increased erythropoiesis, and no jaundice at birth. Flow cytometry revealed that the Jra antigen of red cells in the infant was nearly negative at birth, biphasic at 5â¯weeks, and lowly expressed at 7â¯months of life. We searched online for previous case reports on HDFN due to Jra incompatibility. Among 63 reported cases, excluding 25 cases, 38 were included with the present case for analysis. Of 39 newborns, 10 developed clear anemia (hemoglobin <10.0â¯g/dL), and 1 died, 5 developed hydrops fetalis, 4 needed intrauterine transfusion and/or exchange transfusion, and 3 received red cell transfusion after birth; overlaps were included. Among 29 neonates with no anemia, 8 needed interventions including phototherapy and γ-globulin infusion, and the remaining 21 received conservative supports only. The maternal anti-Jra titer, ranging between 4 and 2048, did not correlate with the severity of anemia, levels of bilirubin, or any interventions required. The DAT of red cells was positive in 29 of 36 fetuses/newborns tested, whereas it was often negative among anemic neonates (4 of 9) (Pâ¯<â¯.05). Hematopoiesis did not increase effectively, as indicated by reticulocyte ratios between 1.7% and 22.3%, even with the increase in reticulocytes in anemic neonates compared with nonanemic neonates (Pâ¯<â¯.05). Total bilirubin levels ranged broadly between 0.2 and 14.3â¯mg/dL but were generally low. The maternal anti-Jra titer and IgG3 subclass did not correlate with the morbidity of the newborns. Being identical/compatible between mothers and their infants may possibly enhance infants' morbidity, as a weak tendency was observed (Pâ¯=â¯.053). Maternal anti-Jra may suppress erythropoiesis in fetuses via a mechanism different from the established HDFN, such as anti-D, as evidenced by the lower reticulocyte count and small increase in bilirubin in neonates. As the anti-Jra titer, IgG subclass, and DAT were not correlated with the severity, the mechanism of anti-Jra-induced HDFN remains to be elucidated.
Assuntos
Incompatibilidade de Grupos Sanguíneos/diagnóstico , Eritroblastose Fetal/diagnóstico , Adulto , Incompatibilidade de Grupos Sanguíneos/sangue , Incompatibilidade de Grupos Sanguíneos/imunologia , Eritroblastose Fetal/sangue , Eritroblastose Fetal/imunologia , Eritropoese , Feminino , Hemólise , Humanos , Recém-Nascido , Masculino , Índice de Gravidade de DoençaRESUMO
ABO blood group incompatibility between mother and fetus can lead to hemolytic disease of the fetus and newborn (HDFN). We present the first case of severe O/A HDFN associated with extremely high-titer (1:32 000) immunoglobulin G anti-A antibodies in a Cameroon mother. Cord blood analysis revealed severe fetal hemolytic anemia and conjugated hyperbilirubinemia. After exclusion of an underlying disease and other risk factors, cholestasis resolved after treatment with ursodeoxycholic acid, a red blood cell transfusion, and intravenous immunoglobulins. This case is presented to create awareness for a more severe course of ABO HDFN in nonwhite and non-European mother-child pairs.
Assuntos
Anticorpos Anti-Idiotípicos/sangue , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Colestase/diagnóstico , Eritroblastose Fetal/diagnóstico , Imunoglobulina G/sangue , Complicações Hematológicas na Gravidez/diagnóstico , Adulto , Incompatibilidade de Grupos Sanguíneos/etiologia , Cesárea/métodos , Colestase/etiologia , Colestase/terapia , Terapia Combinada , Procedimentos Cirúrgicos Eletivos , Eritroblastose Fetal/etiologia , Eritroblastose Fetal/terapia , Feminino , Seguimentos , Idade Gestacional , Humanos , Recém-Nascido , Gravidez , Gravidez de Alto Risco , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do TratamentoRESUMO
BACKGROUND: The ABO transplantation barrier can be breached if antibody is reduced to low levels. Current serologic methods involve testing natural RBCs against dilutions of plasma to determine antibody levels, but these methods are poorly standardized and inherently error prone with consequent large inter- and intra laboratory variation. We evaluated the feasibility of using antigen-standardized kodecytes and undiluted plasma as an alternative method for antibody measurement in patients preparing for ABO-incompatible kidney transplantation. STUDY DESIGN AND METHODS: A panel of five kodecytes, bearing defined levels of synthetic blood group A type 2 antigen was developed (kodecyte assay) to show reaction patterns against undiluted plasma that were indicative of anti-A and anti-A,B levels. This panel was evaluated against the contemporary method of testing dilutions of plasma against A1 cells to determine titer (A1 cell assay) in both column agglutination and tube techniques. Evaluation samples included reference standards, 102 group O plus 23 group B donors, and 40 pre- and post-plasmapheresis samples from five prospective ABO-incompatible kidney transplant patients. RESULTS: Comparisons between the kodecyte and A1 cell assays found greater than 90% correlation for all samples. Tube and column agglutination technology platform differences were observed with A1 cells and kodecytes. Discordant samples were generally found to have high ratios of IgG:IgM or vice versa. CONCLUSIONS: The kodecyte assay is a simple method that requires no sample dilution, and an optimized two-cell kodecyte panel is potentially capable of informing ABO-incompatible kidney transplantation decisions based on antibody levels.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Isoanticorpos/análise , Transplante de Rim/métodos , Plasma/química , Testes Sorológicos/métodos , Incompatibilidade de Grupos Sanguíneos/sangue , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Isoanticorpos/sangue , Transplante de Rim/efeitos adversos , Doadores Vivos , Plasma/imunologia , Plasmaferese , Prognóstico , Estudos ProspectivosRESUMO
We present twins born to the 31-year-old, multigravida mother, who were referred to our centre at 90 hours of life for severe hyperbilirubinaemia. Twin 1 had already received two double volume exchange transfusions at 55 and 83 hours of life, in view of the persistent rise in bilirubin despite receiving phototherapy. Twin 2 had received phototherapy and 1 packed red blood cell transfusion in view of the fall in haematocrit. Mother's blood group was B positive and that of both twins was O positive. Both the twins were started on intensive phototherapy and their serum bilirubin and haematocrit were evaluated. On investigation, a minor blood incompatibility was found. Double volume exchange transfusion was done for twin 2 at 100 hours of life in view of the rapid rise in serum bilirubin. Both the babies were monitored for their serum bilirubin and treated for sepsis and discharged after 15 days.
Assuntos
Bilirrubina/sangue , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Transfusão Total , Hiperbilirrubinemia Neonatal/terapia , Fototerapia/métodos , Gêmeos , Adulto , Incompatibilidade de Grupos Sanguíneos/fisiopatologia , Incompatibilidade de Grupos Sanguíneos/terapia , Transfusão Total/efeitos adversos , Feminino , Hematócrito , Humanos , Hiperbilirrubinemia Neonatal/sangue , Hiperbilirrubinemia Neonatal/fisiopatologia , Recém-Nascido , Masculino , Resultado do TratamentoRESUMO
BACKGROUND: Accommodation in ABO-incompatible (ABOi) transplantation and subclinical antibody-mediated rejection in HLA-incompatible (HLAi) transplantation share several morphological similarities. Because the clinical long-term outcomes differ, we hypothesized different molecular processes involved in ABOi transplantation and subclinical antibody-mediated rejection. METHODS: Using Illumina Human HT-12 v4 Expression BeadChips, the whole transcriptome was evaluated based on 3-month protocol C4d+ biopsies in otherwise stable ABOi and HLAi kidney grafts, as well as in C4d-negative HLA-compatible grafts exhibiting normal histological findings. Top differently regulated genes were further validated using real-time quantitative polymerase chain reaction in another patient cohort and complement regulatory proteins by immunohistochemistry. RESULTS: In the case of genes involved in immune response-related biological processes, ABOi and HLAi cohorts had similar transcriptomic profiles to C4d-negative controls. The majority of deregulated genes in the ABOi and HLAi groups consisted of metallothioneins and epithelial transporter genes. Increased expression of epithelial transporters (SLC4A1, SLC4A9, SLC17A3, SLC12A3, and SLC30A2) and class 1 metallothioneins (MT1F, MT1G, and MT1X) in HLAi transplantation was validated by real-time quantitative polymerase chain reaction. In comparison to controls, both incompatible cohorts were characterized by the upregulation of intrarenal complement regulatory genes. CD46 and CD59 transcripts were increased in the ABOi cohort, whereas CD46 solely in HLAi group, and CD59 protein expression was similar in both incompatible groups. CONCLUSIONS: Several epithelial transporters and metallothioneins discriminate subclinical antibody-mediated rejection in HLAi transplantation from accommodation in ABOi transplantation, which suggest different involved downstream mechanisms and increased risk of injury in HLAi settings. Metallothioneins with their antioxidative properties may help to attenuate the inflammation response induced by donor-specific anti-HLA antibody binding.
Assuntos
Incompatibilidade de Grupos Sanguíneos/diagnóstico , Rejeição de Enxerto/diagnóstico , Transplante de Rim/efeitos adversos , Sistema ABO de Grupos Sanguíneos/imunologia , Adulto , Idoso , Aloenxertos/imunologia , Aloenxertos/metabolismo , Aloenxertos/patologia , Biomarcadores/metabolismo , Biópsia , Incompatibilidade de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/patologia , Feminino , Seguimentos , Perfilação da Expressão Gênica , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/patologia , Sobrevivência de Enxerto/imunologia , Antígenos HLA/imunologia , Humanos , Isoanticorpos/imunologia , Rim/imunologia , Rim/metabolismo , Rim/patologia , Masculino , Proteínas de Membrana Transportadoras/metabolismo , Metalotioneína/metabolismo , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto JovemRESUMO
Passenger lymphocyte syndrome is a rare but important disease in which the donor lymphocytes produce antibodies to the red blood cell antigens of the recipient, causing alloimmune hemolysis. It occurs in ABO blood group-mismatched solid-organ and/or bone marrow transplant. We report a case of passenger lymphocyte syndrome occurring after ABO-incompatible kidney transplant. The recipient received rituximab as a desensitization protocol. On posttransplant day 18, the recipient showed a fall in her hemoglobin levels without identifiable bleeding source and an elevation of total bilirubin. Although hemolytic anemia was suspected, schizocytes on the peripheral smear were not observed. Anti-B-type antibodies were detected, and a diagnosis of passenger lymphocyte syndrome was confirmed. The patient was successfully treated with steroid pulse therapy, an increase of mycophenolate mofetil to 2 g/day, and conversion from cyclosporine to tacrolimus. To our knowledge, this is the first demonstration of passenger lymphocyte syndrome in an ABO-incompatible kidney recipients receiving rituximab.
Assuntos
Sistema ABO de Grupos Sanguíneos , Anemia Hemolítica Autoimune/imunologia , Incompatibilidade de Grupos Sanguíneos/imunologia , Hemólise , Histocompatibilidade , Imunossupressores/efeitos adversos , Transplante de Rim/efeitos adversos , Rituximab/efeitos adversos , Anemia Hemolítica Autoimune/sangue , Anemia Hemolítica Autoimune/diagnóstico , Anemia Hemolítica Autoimune/tratamento farmacológico , Incompatibilidade de Grupos Sanguíneos/sangue , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Feminino , Humanos , Pessoa de Meia-Idade , Fatores de Risco , Síndrome , Resultado do TratamentoRESUMO
OBJECTIVES: Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors. MATERIALS AND METHODS: Our study included 17 recipients of ABO-incompatible kidney transplant procedures performed at our institution. At baseline and at 3 and 12 months after conversion, graft biopsies were performed to check for acute rejection and C4d deposition. RESULTS: Treatment with everolimus was stopped due to adverse events in 8 patients (47.1%). Conversion to everolimus with calcineurin inhibitor minimization did not induce acute rejection or C4d deposition at 3 and 12 months after conversion in ABO-incompatible kidney transplant recipients in whom everolimus was maintained or stopped within 1 year after conversion. CONCLUSIONS: Everolimus elicited no acute rejection and no C4d deposition, whether everolimus was maintained or stopped within 1 year after conversion, in ABO-incompatible kidney transplant recipients.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/imunologia , Substituição de Medicamentos , Everolimo/administração & dosagem , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto/efeitos dos fármacos , Histocompatibilidade , Imunossupressores/administração & dosagem , Transplante de Rim , Ácido Micofenólico/administração & dosagem , Adulto , Idoso , Incompatibilidade de Grupos Sanguíneos/diagnóstico , Complemento C4b/imunologia , Everolimo/efeitos adversos , Feminino , Seguimentos , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/imunologia , Humanos , Imunossupressores/efeitos adversos , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/efeitos adversos , Fragmentos de Peptídeos/imunologia , Projetos Piloto , Estudos Prospectivos , Fatores de Tempo , Resultado do TratamentoRESUMO
ABO incompatibility (ABOi), the most common cause of hemolytic disease of the newborn (HDN), is nearly always mild and treatable with phototherapy. Reports of ABOi HDN requiring neonatal exchange transfusion are extremely rare since the inception of modern guidelines. Here, a case of ABOi HDN clearly met criteria for exchange transfusion. An O-positive African American mother delivered a B-positive neonate that quickly developed hyperbilirubinemia. The neonatal DAT was positive from anti-B and anti-A,B, and maternal IgG titer was 1024. Double volume exchange transfusion resulted in a favorable outcome. Given early discharge of newborns, further understanding of factors predicting severe disease is needed.